10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Edoxaban

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Edoxaban

Edoxaban

Class : A

Show all info

Print

Contact us

  1. Yin OQ, Miller R. Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers. Clin Drug Investig. 2014;34:743-52.

  2. Chen X, Liu D, Wu Y, Song H, Liu Y, Jiang J et al. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers. Xenobiotica. 2016:1-8.

  3. Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2016;55:641-55.

  4. Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants A meta-analysis of the interventional trials. Int J Cardiol. 2016;212:255-8.

  5. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15.

  6. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement A randomised double-blind dose-response study. Thromb Haemost. 2010;104:642-9.

  7. Rohatagi S, Mendell J, Kastrissios H, Green M, Shi M, Patel I et al. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. Thromb Haemost. 2012;108:887-95.

  8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104.

  9. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014;134:774-82.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-10-17.]

  1. Yin OQ, Miller R. Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers. Clin Drug Investig. 2014;34:743-52.
  2. Chen X, Liu D, Wu Y, Song H, Liu Y, Jiang J et al. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers. Xenobiotica. 2016:1-8.
  3. Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2016;55:641-55.
  4. Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants A meta-analysis of the interventional trials. Int J Cardiol. 2016;212:255-8.
  5. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15.
  6. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement A randomised double-blind dose-response study. Thromb Haemost. 2010;104:642-9.
  7. Rohatagi S, Mendell J, Kastrissios H, Green M, Shi M, Patel I et al. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. Thromb Haemost. 2012;108:887-95.
  8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104.
  9. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014;134:774-82.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-10-17.]